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Vamadevan S. Ajay1,16, V. Usha Menon3, Premlata K. Varthakavi4, Vijay Viswanathan5, Mala Dharmalingam6,
Ganapati Bantwal7, Rakesh Kumar Sahay8, Muhammad Qamar Masood9, Rajesh Khadgawat10, Ankush Desai11,
Dorairaj Prabhakaran12,16,17, K. M. Venkat Narayan13, Victoria L. Phillips14, Nikhil Tandon15 and On behalf of the
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Abstract
Background: Economic dimensions of implementing quality improvement for diabetes care are understudied
worldwide. We describe the economic evaluation protocol within a randomised controlled trial that tested a multi-
component quality improvement (QI) strategy for individuals with poorly-controlled type 2 diabetes in South Asia.
Methods/design: This economic evaluation of the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS)
randomised trial involved 1146 people with poorly-controlled type 2 diabetes receiving care at 10 diverse diabetes
clinics across India and Pakistan. The economic evaluation comprises both a within-trial cost-effectiveness analysis
(mean 2.5 years follow up) and a microsimulation model-based cost-utility analysis (life-time horizon). Effectiveness
measures include multiple risk factor control (achieving HbA1c < 7% and blood pressure < 130/80 mmHg and/or
LDL-cholesterol< 100 mg/dl), and patient reported outcomes including quality adjusted life years (QALYs) measured
by EQ-5D-3 L, hospitalizations, and diabetes related complications at the trial end. Cost measures include direct
medical and non-medical costs relevant to outpatient care (consultation fee, medicines, laboratory tests, supplies,
food, and escort/accompanying person costs, transport) and inpatient care (hospitalization, transport, and accompanying
person costs) of the intervention compared to usual diabetes care. Patient, healthcare system, and societal perspectives
will be applied for costing. Both cost and health effects will be discounted at 3% per year for within trial cost-effectiveness
analysis over 2.5 years and decision modelling analysis over a lifetime horizon. Outcomes will be reported as the
incremental cost-effectiveness ratios (ICER) to achieve multiple risk factor control, avoid diabetes-related complications, or
QALYs gained against varying levels of willingness to pay threshold values. Sensitivity analyses will be performed to assess
uncertainties around ICER estimates by varying costs (95% CIs) across public vs. private settings and using conservative
estimates of effect size (95% CIs) for multiple risk factor control. Costs will be reported in US$ 2018.
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Discussion: We hypothesize that the additional upfront costs of delivering the intervention will be counterbalanced by
improvements in clinical outcomes and patient-reported outcomes, thereby rendering this multi-component QI
intervention cost-effective in resource constrained South Asian settings.
Trial registration: ClinicalTrials.gov: NCT01212328.
Keywords: Economic evaluation, Diabetes care, Multicomponent strategy, Quality improvement, South Asia
Background
Diabetes is one of the fastest growing public health prob-
lems with huge financial burdens. The global costs of dia-
betes were US$ 1.31 trillion (1.8% of global GDP) in 2015
[1]. A 2018 systematic review found that annual costs of
diabetes care (out of pocket medical expenditure) in South
Asia ranged between US$ 575 to US $1216 per person [2].
Diabetes is a progressive disease which requires increas-
ingly more clinic visits, laboratory tests, and patients need
to engage with the healthcare system and providers over
years for better management of diabetes which can arrest
disease progression. However, current chronic care for
diabetes is sub-optimal, costly, and lower socioeconomic
status or uninsured individuals may be more likely to
experience poor control [3–7].
Several barriers at the patient- (e.g., low motivation,
financial barriers), provider- (e.g., inertia to intensify
treatments), and system-level (e.g., complicated and/or
fragmented care system), individually or together, cause
patient and system “fatigue” and disrupt achievement of
diabetes care goals [8–10]. In the Centre for Cardio-
metabolic Risk Reduction in South Asia (CARRS) Trial,
we targeted different levels of barriers together (e.g.,
patient motivation and provider inertia) [9, 11] and dem-
onstrated sustainable and larger improvements in out-
comes and satisfaction for people with diabetes with a
multicomponent strategy of decision support-electronic
health records (DS-EHR) and non-physician care coordi-
nators (CC), compared to usual diabetes care [12].
However, enhancements or changes to the status quo
of care delivery come at a cost, and in order to formulate
useful recommendations for practicing clinicians, health
systems, payers (health insurance, governments, patients
paying out-of-pocket), and policymakers, there is an
imperative to assess the value of investing in quality im-
provement (QI) care models. Knowing the upfront costs
is also necessary to guide decision makers as they con-
sider implementation of QI interventions in clinical care.
A 2018 systematic review of economic evaluations of
QI interventions for glycaemic control among adults
with type 1 or type 2 diabetes from high income coun-
tries found that multifaceted QI interventions that lower
HbA1c was good value for money versus usual care, de-
pending on society’s willingness to pay [13]. However, in
our review of cost-effectiveness of interventions to
control cardiovascular diseases and diabetes mellitus, we
found a scarcity of cost-effectiveness studies related to
QI interventions for diabetes care in South Asia [14].
Here, we describe the economic evaluation protocol to
assess the within-trial cost-effectiveness and broader so-
cietal value of the CARRS diabetes care model consisting
of DS-EHR and non-physician CCs compared to usual
diabetes care.
Methods/Design of Economic Evaluation
Overview
The objectives of the economic evaluation are to assess:
a) the incremental cost of delivering multicomponent QI
interventions compared to usual diabetes care in tertiary
care settings over a period of 2.5 years; b) whether the
intervention provides value for money (cost-effective-
ness) to patients, healthcare systems and society than
usual care, and if so; c) the extent of uncertainty over
the cost-effectiveness of the intervention and value of
conducting further research to reduce this uncertainty.
The CARRS Trial’s economic evaluation will follow
standard international methodological guidelines [15–
18]. Given, more than 80% of medical expenses in India
and Pakistan are out-of-pocket expenditures borne by
the patient, we will apply the patient viewpoint as the
predominant perspective, in addition to healthcare sys-
tem and societal perspectives for costing resource use.
Cost data will be reported in 2018 United States Dollars
(US$). Both cost and health effects will be discounted at
3% per year as per the World Health Organization’s
(WHO) guidelines for conducting economic evaluations
in developing countries.
The CARRS trial and study population
The CARRS Trial randomised 1146 eligible patients
with poorly controlled type 2 diabetes (HbA1c > 8%
and SBP > 140 mmHg or LDLc> 130 mg/dl) to inter-
vention (n = 575) or usual care (n = 571) across 10
diverse diabetes clinics in India and Pakistan. At base-
line, participants’ mean age was 54 years, 45% were
males, mean HbA1c was 9.9%, LDLc 123.2 mg/dl, BP
144.2/82.3 mmHg, and median duration of diabetes
was 7 years [12].
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Intervention and comparator
Detailed information about the CARRS-Trial intervention
and protocol has been published previously [19]. Briefly,
the CARRS intervention consisted of DS-EHRs to en-
hance physicians’ responsiveness to consider treatment
modification and non-physician CCs to support patients
in their adherence to prescribed therapies. The DS-EHR
stored all consultation, laboratory, self-care, and diabetes
related complications data for patients in one easily ac-
cessible web portal to monitor patient progress; and pro-
vided decision-support system (DSS) prompts to facilitate
achievement of guideline-recommended glycemic, blood
pressure, and lipid goals. The CCs fully managed the
DS-EHR data-entry for intervention group participants
and all communication of DSS prompts to the physician
during consultations via print-out or electronic display.
Physicians could, at their discretion, accept or reject DSS
prompts and modify treatment plans based on clinical
judgment, so long as justification was provided.
The intervention was compared with usual diabetes
care at nine clinics/hospitals across India and one site in
Pakistan. Figure 1 demonstrates the study flow.
Effectiveness measures
To evaluate incremental effectiveness, we will compare
the proportions of intervention and control arm partici-
pants achieving multiple risk factor control defined as
HbA1c < 7% and BP < 130/80mmHg or LDLc< 100mg/dl
(and < 70mg/dl for those with history of cardiovascular
disease). Data on health-related quality of life (EQ5D-3 L);
new-onset cardiovascular events, new onset microvascular
events, and other hospitalizations would also be used.
The CARRS Trial is currently ongoing and we will
project cardiovascular and microvascular outcomes
using proxy indicators (intermediate risk factors: HbA1c,
BP, LDLc). Relative risk reductions for major adverse
cardiovascular events with intervention or comparator
will also be calculated separately for each participant,
using United Kingdom Prospective Diabetes Study
(UKPDS) Outcomes Models 2 which has been validated
for use in South Asians [20]. Table 1 summarizes the
study outcomes (effectiveness measures) to be consid-
ered in the cost-effectiveness analysis.
Resource use and cost data
Resource utilization and costs will be estimated using data
from the CARRS Trial population (1146 participants).
The study paid the costs of annual laboratory investiga-
tions, but patients had to bear the cost of clinic visits and
laboratory tests for regular follow-up visits or any other
interim clinic visits, tests, medication changes, or proce-
dures advised by the treating physician. CARRS Trial data
will be extracted from clinic and study records for the
following: medication use, laboratory tests, consultations
with healthcare professionals (outpatient attendance for
diabetes); preventive screening (eye examination, foot
examination, ECG, microalbuminuria test), emergency de-
partment attendances (when not admitted to hospital);
and serious adverse events (including all hospital
admissions).
Patients’ self-reported expenditures and costs of out-
patient visits and hospitalizations related to diabetes
complications will be extracted from the trial annual
visit case report forms (CRF). Out-of-pocket expenses
reported by the patients will permit estimation of eco-
nomic value from the patient’s perspective.
To estimate value from a healthcare system perspective,
unit costs for outpatient visits and in-patient hospitaliza-
tions, and processes of care measures including preventive
examinations will be obtained from participating hospitals.
For treatment of cardiovascular and microvascular events,
we will extract detailed information concerning diagnosis;
length of hospital stay; diagnostic/therapeutic procedures
and any ongoing treatment and support. Additionally, the
unit price of medications will be obtained from the Phar-
maTrac database for January 2014 [21]. PharmaTrac pro-
vides the market retail price (MRP) of all drugs by drug
class, brand name, generic composition, formulation
(oral/injectables), dose, and packs being sold in India.
PharmaTrac has an extensive coverage of drug retailers
and is believed to be a reliable source to estimate unit cost
of drug prices in India. The IMS Health drug database will
be used to estimate drug prices in Pakistan.
To estimate costs from the societal perspective, indirect
costs due to lost productivity (number of work days missed
due to out-patient or in-patient care) will be valued using
the human capital approach [22]. Finally, total costs over
the trial period and annual cost per patient (both undis-
counted and discounted) will be estimated for individual
patients by multiplying resource use by unit costs.
Intervention costs
Intervention development and delivery costs will be derived
from the CARRS Trial expense records (accounts register)
and will be estimated from the health system perspective.
Intervention costs include DS-EHR development, imple-
mentation, and maintenance costs; intervention training;
care coordinator salary; and the incremental health care
costs associated with the intervention delivery (i.e. the costs
of additional medicines, additional clinic visits that patients
bear and whether it is different between the treatment
groups). These costs will be calculated as average costs of
implementation per person and exclude any research spe-
cific costs. The cost estimates assume that the DS-EHR is
implemented in a relatively large tertiary care hospital hav-
ing additional resource facilities to implement the interven-
tion (i.e. workspace for the care coordinator, and access to
internet service providers is considered a maintenance
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cost). DS-EHR development and maintenance costs will in-
clude software programmer’s time, expert consultant’s/phy-
sicians time in developing and reviewing the diabetes
management algorithm. DS-EHR implementation cost will
include care coordinators and site physician’s time to enter
patient details in the EHR system and review of software
generated diabetes management plans, respectively. Inter-
vention training costs include training materials, the time
of the trainers and the staff participating in the training,
and training for physicians to use the DS-EHR algorithms.
These costs will be estimated using the study’s accounting
data. Training material and time costs will be estimated
from the first year of the intervention. Tables 2 and 3
present an overview of cost measures, health service use,
and source of data.
Within trial cost-effectiveness analysis
Based on estimates of between-group differences in mean
healthcare costs and outcomes (adjusting for differences
in baseline characteristics) over the study period, we will
estimate the following incremental cost-effectiveness
ratios (ICERs):
 Incremental cost per primary outcome achieved (i.e.
multiple risk factor control: HbA1c < 7% and BP <
130/80 mmHg and/or LDLc< 100 mg/dl)
Fig. 1 Study flow - Economic evaluation alongside CARRS Trial. Abbreviations: CARRS=Centre for Cardiometabolic Risk Reduction in South Asia),
DS-EHR = decision-support electronic health records; HbA1c = glycated hemoglobin, BP = blood pressure, SBP = systolic blood pressure, LDLc =
low-density lipoprotein cholesterol, EQ5D-3 L = European quality of life 5 dimension 3 levels; mg/dl = milligrams per deciliter, mmHg =millimeter
of mercury
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 Incremental cost per unit reduction in single risk
factors: HbA1c (1% point reduction), SBP (5 mmHg
reduction), and LDLc (10 mg/dl reduction)
 Incremental cost per quality adjusted life years
(QALYs) gained
Non-parametric bootstrapping will be used to report
95% confidence intervals around the ICER estimates [23].
ICERs will be reported in US$ 2018. Cost effectiveness
acceptability curves against a wide range of willingness to
pay values will be presented [24]. Cost-effectiveness results
will be also presented by major sub-groups: age, gender,
education, income level, types of health setting (public,
private or semi-private) and history of macro- and micro-
vascular complications.
Missing data
The CARRS Trial has a minimal loss to follow-up in-
cluding consent withdrawals and deaths at 2.5 years
(9.2%) but, if needed; multiple imputation approaches
will be used to handle missing outcomes data [12]. For
EQ5D-3 L scores, which will be used for QALY estima-
tion, we will follow the developer’s guideline for miss-
ing data; that is, missing data will be handled by
imputing values within each dimension [25–28]. To
address potential biases due to incomplete follow-up,
we will use multiple imputation approaches to replace
missing cost values if missing data accounts for more
than 10% of a domain/variable [29–31]. Since cost data
are unlikely to be normally distributed, [29] we will use
the multiple imputation chained equations approach to
impute missing cost data. Costs will be imputed at the
total cost level [29].
Decision-modeling based cost-utility analysis
A decision-analytic microsimulation model will be devel-
oped to evaluate long-term costs and health consequences
of delivering care for people with type 2 diabetes using a
multicomponent QI strategy rather than current standard
care approaches. A microsimulation model is chosen as it
is very flexible and can reflect complex treatment pathways
and relationships between individuals’ characteristics, his-
tories, and outcomes; it can be used to examine the impact
of real resource constraints within a healthcare system.
The microsimulation decision model will be imple-
mented using appropriate software: STATA or a program-
ming language (e.g. R). To assure the credibility of our
model, we will follow international guidelines for verifica-
tion and validation of decision models [32].
Model analysis
All analyses will compare results for the CARRS multicom-
ponent QI care delivery model versus usual diabetes care.
In the CARRS Trial microsimulation model, costs and
QALYs will be recorded for each individual and an average
cost and QALY for the simulated population will be esti-
mated. The microsimulation model will be run twice, once
to simulate costs and QALYs under usual care and the
other to simulate costs and QALYs under the intervention
scenario (multicomponent QI strategy). Individuals
representing the CARRS trial inclusion criteria will enter
the model and their baseline risk for CVD events and
diabetes-related microvascular complications will be esti-
mated using the UKPDS Outcomes Model 2 algorithm.
Costs and QALYs will be recorded for each event (includ-
ing adverse events). Individuals can experience more than
one event (model run for lifetime horizon) and patient
Table 1 Overview of the effectiveness measures
Measure Means of collection Timing of collection Source of data
Multiple risk factor control (HbA1c < 7% and
BP < 130/80mmHg or LDLc< 100mg/dl)
Blood test + BP measurement
using digital BP monitor
Baseline: Prior to intervention deliveryFollow-up:
Annual visits post intervention delivery
Trial eCRF
(Form C, E, F)
Single risk factor control
HbA1c (1% point reduction) Fasting blood test Baseline: Prior to intervention deliveryFollow-up:
Annual visits post intervention delivery
Trial eCRF
(Form C, E, F)
SBP (5 mmHg reduction) BP measurement using digital
BP monitor (Omron-T9P)
Baseline: Prior to intervention deliveryFollow-up:
Annual visits post intervention delivery
Trial eCRF
(Form C, E, F)
DBP (5 mmHg reduction) BP measurement using digital
BP monitor (Omron-T9P)
Baseline: Prior to intervention deliveryFollow-up:
Annual visits post intervention delivery
Trial eCRF
(Form C, E, F)
LDLc (10 mg/dl reduction) Fasting blood test Baseline: Prior to intervention deliveryFollow-up:
Annual visits post intervention delivery
Trial eCRF
(Form C, E, F)
Major adverse cardiovascular events Self-reported by patient and
physician verified
Follow-up: All study related and non-study related
clinic visits
Trial eCRF
(form X)
Diabetes related micro-vascular
complications
Self-reported by patient and
physician verified
Follow-up: All study related and non-study related
clinic visits
Trial eCRF
(form X)
Quality adjusted life years EQ5D-3 L Baseline: Prior to intervention deliveryFollow-up:
Annual visits post intervention delivery
Trial eCRF
(Form C, E, F)
HbA1c Glycated haemoglobin, SBP Systolic blood pressure, LDLc Low-density lipoprotein cholesterol, eCRF Electronic case report form, EQ5D-3 L European Quality
of Life five dimension 3 levels, BP Blood pressure, mg/dl Milligrams per deciliter, mmHg Millimeter of mercury
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Table 2 Overview of cost measures
Type of cost Level Expense type Cost component Means of collection Timing of collection Source of data
Direct Intervention Fixed cost Software development Trial records After completion of
software development
Developers of
software: DS-EHR
Fixed cost Training of physicians and
care coordinators
Trial records After completion of
training
Trial Team
Fixed cost Laptop Trial records Baseline (at the start
of the trial)
Trial records
Fixed cost Mobile phone Trial records Baseline (at the start
of the trial)
Trial records
Variable cost Care coordinator’s salary Trial records Monthly Payment invoice
Variable cost Three-monthly laboratory tests Interview with patients Annual Self-reported by
patient
Variable cost Internet Trial records Annual Payment invoice
Variable cost Communication cost Trial records Annual Payment invoice
Fixed cost Software maintenance Trial records Annual Payment invoice
Clinic/
Hospital
Variable cost Physician’s time Interview with patients
and physicians
Annual Self-reported by
physicians
Variable cost Resource use for patient
management: telephone
calls, letters, team meetings
Interview with physicians
and hospital administrators
Annual Self-reported by
administrators
Patient Variable cost Medications Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Medical supplies (glucose
strips, gauze, sterile solution,
etc.)
Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Laboratory tests Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Diagnostics Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Preventative screening (ECG,
eye exam, foot exam, dental
exam, etc.)
Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Outpatient visits (consultation fee) Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Transportation Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Food (personal) Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Additional cost for escort Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Other out of pocket expenses Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost In-patient hospitalization Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Procedures Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Indirect Patient Variable cost Lost-productivity Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Work days lost due to
out-patient visit
Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost Work days lost due to Interview with patients Annual Self-reported by
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characteristics such as age and history of previous events,
such as a stroke or diabetic retinopathy, will be updated as
the model is being run, with ensuing reflective increases in
the risk of an event. The simulation model will run for a
sufficient number of iterations to provide stable results. If
there is a trade-off between costs and health effects (higher
costs and better health outcomes for the CARRS interven-
tion, or vice versa), the incremental cost per cardiovascular
event averted, incremental cost per diabetes-related micro-
vascular complication averted, and incremental cost per
quality adjusted life year (QALY) gained will be reported.
Projections of cost-effectiveness estimates over a lifetime
horizon will be made for India and Pakistan.
Sensitivity analysis
Several one-way sensitivity analyses will be carried out to
estimate the uncertainties around ICERs. First, to address
the uncertainty around the ICER relating to external valid-
ity, we will carry out sensitivity analyses on the most im-
portant cost drivers (medications, hospitalizations, and
consultation fees) to assess the impact of protocol-driven
healthcare use. Second, total cost will be calculated with
and without the costs of developing the intervention
(DS-EHR) to ascertain whether an increased cost in the
intervention arm could be explained by costs for some of
the components of the intervention. Lastly, sensitivity ana-
lyses would vary the effectiveness of the intervention in trial
vs. non-trial settings based on the lower and upper limit of
95% confidence intervals (CI) of the effect estimates. Re-
sults of probabilistic sensitivity analyses will be presented
using a scatter plot of points on the cost-effectiveness plane
– illustrating the possible ranges of estimates of incremen-
tal costs and incremental QALYs [24].
Discussion
The publication and peer-review of economic evaluation
protocols alongside clinical trials is recommended to
increase transparency and minimise bias [33]. Here, we de-
scribe the protocol of an economic evaluation of a multi-
component QI strategy compared to usual diabetes care in
South Asia from patient, healthcare system, and societal
perspectives. There are very few economic evaluations of
QI strategies for chronic disease management in South
Asia [34] or in LMICs in general, and so this report fills a
gap. Following internationally recognised guidelines [15],
this protocol serves to heighten the transparency of our
economic evaluation approach.
Economic evaluations from high-income countries dem-
onstrate that multifactorial QI strategies are cost-effective.
For example, the STENO-2 study showed that, from a
health care payer perspective in Denmark, intensive multi-
factorial intervention was more cost-effective than conven-
tional treatment (ICER: €2538 or US$ 2954 per QALY
gained) over a lifetime horizon [35]. Increased costs with
intensive treatment were due to increased pharmacy and
consultation costs. However, this also resulted in more
Table 2 Overview of cost measures (Continued)
Type of cost Level Expense type Cost component Means of collection Timing of collection Source of data
in-patient hospitalization + Trial eCRF patient in eCRF
Variable cost loss of concentration Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
Variable cost loss of function (health
utility index)
Interview with patients
+ Trial eCRF
Annual Self-reported by
patient in eCRF
DS-EHR Decision-support Electronic Health Records, ECG Electrocardiogram, eCRF Electronic case report form
Table 3 Self-reported health services use and sources of data
Service type Source of unit costs
Outpatient clinic visit OOP
HbA1c testing OOP
Cholesterol testing OOP
Foot examination at clinic OOP
Eye examination OOP
Microalbuminuria check OOP
ECG OOP
Dental exam OOP
Dietician visit OOP
Diabetes educator visit OOP
Other healthcare practitioner visits OOP
Time spent commuting to clinic Wage loss due to
missed work days
Time spent for lab tests including waiting Wage loss due to
missed work days
Time spent waiting for consultation Wage loss due to
missed work days
Time spent in-person with doctor Wage loss due to
missed work days
Time spent with dietician, nurse of
clinic-staff receiving self-care education
Wage loss due to
missed work days
Other time for check-out including
medications
Wage loss due to
missed work days
Hospitalization OOP
Emergency room visit OOP
Medications Pharmatrac/IMS/OOP
Abbreviations: OOP Out of pocket medical expenses, HbA1c Glycated
haemoglobin, ECG Electrocardiogram
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QALYs gained for intensive treatment versus conventional
treatment (+ 1.66 QALYs). The ADDITION-UK trial
based cost-effectiveness analysis comparing intensive
versus conventional treatment demonstrated an ICER of
£71,232 (US$93566)/QALY, £28,444 (US$37362)/QALY,
and £27,549 (US$36186)/QALY over 10-, 20-, and 30-year
time horizons respectively [36]. Given the United
Kingdom’s willingness-to-pay thresholds in patients with
diabetes, intensive treatment was of borderline cost-effect-
iveness over a time horizon of ≥20 years. The estimates of
cost-effectiveness from the CARRS Trial will provide
much needed data on whether a simple multifactorial
intervention can improve health outcomes with modest
increases in costs in resource-constrained settings.
To enhance external validity, it is recommended that
evaluations using randomised controlled trials should
identify threats to validity such as recruitment/selection
bias, protocol-driven utilisation, and enhanced compli-
ance [34, 37]. Regarding recruitment biases, the CARRS
Trial’s multicentre approach and inclusion of public, pri-
vate, and semi-private practices increases the generalis-
ability and transferability of our economic evaluation
findings [38]. Further, we will extrapolate the decision
analytic microsimulation model beyond the within-trial
analysis by using a sample population of poorly con-
trolled type 2 diabetes patients in India / Pakistan strati-
fied by age-group, gender, and location. Also, although
Markov models can also be adapted for this purpose,
microsimulation models are better suited for analysis of
a mixed population with both incident and prevalent
diabetes complications (cardiovascular diseases and
microvascular events) [39].
This study has several strengths. First, the economic
evaluation protocol follows recognised international guide-
lines to design and report on the relative costs and benefits
of an intervention tested in a randomised trial [15, 37].
Second, the economic evaluation will include individual
patient-level data over a lengthy 2.5 years of follow up,
which are preferable for economic evaluations [15]. Im-
portantly, these patient-level data include objective mea-
sures of health outcomes, health service use, and medicine
use, all obtained during the trial [40]. Reliable economic
evaluations are crucial to shape healthcare policy, in par-
ticular when the possibility of bias in economic evidence
has been minimised by randomisation [40]. Third, our
cost-effectiveness results will also provide a range of values
for both the cost of achieving multiple risk factor targets
but also costs to achieve single and combined risk factor
improvements from poorly controlled baseline values
(mean baseline HbA1c = 9.9) from various perspectives
(patient, healthcare system and societal). Given a large
proportion of healthcare in South Asia is paid for
out-of-pocket, our economic analyses consider that sce-
nario explicitly with a patient perspective analysis. Fourth,
our proposed micro-simulation model based on UKPDS
Outcomes Model 2 will enable long-term cost-effective-
ness analysis and a population budget impact analysis
which will provide cross-sectional estimates of population
impact by year for planning purposes and scalability of the
intervention.
This study has a few noteworthy limitations. First, reli-
ance on patient self-reported out-of-pocket medical cost
data may impact the validity of study results. A 2016 sys-
tematic review of validated self-reported questionnaires to
measure resource utilization and costs in economic evalu-
ation concluded that self-reported questionnaires had good
agreement with administrative data and are a valid method
of collecting data on health resource utilization and associ-
ated costs [41]. However, to overcome any reporting bias
in self-reported costs data, a sub-set of self-reported costs
will be verified against the administrative data and we will
carry out several one-way and probabilistic sensitivity ana-
lyses around the self-reported costs in the microsimulation
model to estimate the confidence in the reported ICER
values. Another limitation of the proposed evaluation is
that in India and Pakistan, there is not an explicit willing-
ness to pay threshold for reduction of cardiovascular risk
in people with diabetes, or an explicit willingness to pay
threshold for cost per unit reductions in CVD risk factors.
As such, it is hard to declare how patients value the inter-
vention. The Commission for Macroeconomics and Health
recommends using a threshold of 1-3x GDP per capita per
QALY gained or DALYs averted to define cost-effectiveness
of a new intervention when conducting global or regional
economic evaluations [16, 42]. Although arbitrary, we will
use this threshold as it has been used previously and has
some philosophical underpinnings [43]. We will apply
these and then perform a sensitivity analysis for the main
economic outcome and present the cost-effectiveness re-
sults on a cost-effectiveness acceptability curve considering
a wide range of willingness to pay values. Common to all
cost-effectiveness analyses conducted alongside rando-
mised trials, external validity of the results may be influ-
enced by restrictive inclusion criteria and protocol-driven
resource use, among other factors [15, 37]. Therefore, we
will conduct a range of sensitivity analyses around key vari-
ables (cost drivers, total cost calculated with and without
the cost of the intervention development, patient charac-
teristics, and effectiveness of the intervention) to address
the uncertainties around the ICERs.
In conclusion, we hypothesise that the additional
upfront cost of delivering the intervention will be
counterbalanced by improvements in clinical practice
and patient related outcomes, thereby rendering the
CARRS QI strategy cost-effective. The results of this
study will be of immediate relevance for decision
makers of all sorts –patients, healthcare providers,
and policy makers– concerning implementation of
Singh et al. Global Health Research and Policy             (2019) 4:7 Page 8 of 10
this healthcare delivery intervention to improve dia-
betes care goals.
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